Grab Sources And More Here: Company Website. Company Presentation. -----
As mentioned above, (NYSE American: MAIA) has several explosive potential catalysts to consider right now. Check these out:
#1. MAIA Potential Catalyst - One Analyst's Target Suggests Over 1,000% Potential Upside From MAIA's Current Chart Levels.
This month, Robert LeBoyer, Senior Vice President and equity research analyst with Noble Life Science Partners, reiterated a $14.00 target on MAIA.
From Tuesday's closing valuation, that provides MAIA with upside potential over 1,000%!
Check out some key report highlights:
Conclusion. Patients in the trial had advanced disease with relapsed NSCLC. We see these data as additional evidence of a sustainable response from combination treatment with ateganosine and cemiplimab. These data are consistent with prior findings showing improvements in overall survival, progression-free survival, and median survival in patients with ICI-resistant and chemo-resistant NSCLC. We are reiterating our Outperform rating and $14 price target. -----
#2. MAIA Potential Catalyst - Another Analyst Target Suggests Over 700% Potential Upside From Tuesday's Close.
Last month, an analyst at Diamond Equity Research provided an update note on their (NYSE American: MAIA) coverage.
In the update, they retagged MAIA with a target of $10.27.
From Tuesday's close, that target provides MAIA with a potential upside of over 700%.
Here's some highlights from the report:
Valuation - Building on the strengthened balance sheet and improved funding visibility, we have revisited our underlying assumptions for THIO in NSCLC. We increase our probability of success (PoS) from 25% to 35%, reflecting the program’s advancement into a pivotal Phase 3 trial, supportive efficacy signals observed in earlier studies, and regulatory momentum, including Fast Track designation. In our view, the transition into a registrational study represents the achievement of a key clinical milestone and enhances visibility into the development pathway.
...
Based on these revised assumptions, alongside our updated comparable company analysis, we derive an illustrative valuation of $10.27 per share, contingent on successful execution by the company. -----
#3. MAIA Potential Catalyst - A Phase 2 Expansion Trial Into The U.S. Signals A Key Company Milestone.
MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer
Exceptional measures of efficacy observed in THIO-101 Phase 2 trial to date include disease control, response rates, and survival data well above standard of care benchmarks
50,000 advanced NSCLC diagnoses in the U.S. annually
CHICAGO, April 16, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the first U.S. clinical site in its Phase 2 THIO-101 expansion trial of its lead investigational therapy as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).
“We are thrilled to activate the expansion of our Phase 2 THIO-101 trial in the U.S., bringing our novel treatment to our country’s broad underserved NSCLC patient population. Every year, we estimate approximately 50,000 patients resistant to chemo and CPIs alone advance to third-line NSCLC in the U.S. The medical need is extensive,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA.
The trial’s expansion into the U.S. marks a key milestone for MAIA, which is expected to open a significantly larger patient pool for evaluation of ateganosine, a novel dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. In addition to the first location, Summit Medical Group in New Jersey, MAIA intends to open four additional sites in U.S. in 2026. The trial is ongoing in Europe and Asia with 44 active sites in 6 countries.
...
Read the full article here. -----
#4. MAIA Potential Catalyst - A Recent $33Mn Capital Raise Aims To Completely Fund An Ongoing Pivotal Phase 3 Trial.
MAIA Biotechnology Expects Recent $33Mn Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy
Strong participation in recent $33Mn common st-ock offering highlights ... confidence in late-stage clinical momentum and commercial potential
Statistical assessments point to high probability of technical success in Phase 3 full approval trial
FDA granted Fast Track designation for dual mechanism therapy as a treatment for non-small cell lung cancer (NSCLC)
CHICAGO, April 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that net proceeds from its $33Mn public offering of common st-ock in March 2026 are expected to fully fund the Company’s ongoing pivotal Phase 3 clinical trial of its lead investigational therapy, ateganosine, as a treatment for non-small cell lung cancer (NSCLC). Ateganosine is a dual mechanism therapy designed to break down telomere structure and function in cancer cells while inducing immune activation. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the drug in third line (3L) NSCLC treatment.
“We are grateful for the support and confidence shown by the heal-th-care-dedicated in-vest-ors and existing shareholders who participated in our recent offering. The $33Mn raise is expected to complete the necessary funding for our pivotal Phase 3 trial through completion,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA
“Statistical assessments point to a high probability of technical success in the third-line setting if Phase 3 data is consistent with our Phase 2 trial results,” Dr. Vitoc continued. “Interim data from the Phase 3 trial, expected next year, may support a discussion with the FDA to present our case for early full commercial approval in third-line NSCLC.”
...
Read the full article here. -----
#5. MAIA Potential Catalyst - The Company Reports Overall Survival Beyond 2 Years For 8 Patients In Ongoing Phase 2 Clinical Trial.
MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
Potential breakthrough therapeutic targets $50Bn+ global immunotherapy market
CHICAGO, March 31, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced highlights from a poster presented on March 27, 2026, at the European Lung Cancer Congress 2026 (ELCC), a premier thoracic oncology forum held March 25-28, 2026, in Copenhagen, Denmark.
MAIA reports overall survival (OS) beyond two years for eight patients treated with ateganosine sequenced with cemiplimab in Parts A and B of its ongoing Phase 2 THIO-101 clinical trial in non-small cell lung cancer (NSCLC). The patients did not receive subsequent lines of therapy.
The eight patients featured in the poster include:
- 1 patient in third-line (3L) therapy with survival of 33 months. Expected survival in this heavily pre-treated population is 5.8 months.
- 4 patients in 2L therapy with survival over 30 months. Documented OS for standard of care treatment (chemotherapy or checkpoint inhibitors alone) in second-line (2L) therapy is 10.5 months.
- All patients have failed previous treatment (prior to THIO-101) with a checkpoint inhibitor (CPI) alone.
- All patients completed 29-34 cycles of therapy, except for 1 patient who completed 2 cycles of therapy with survival follow-up of 725 off therapy.
- 5 of the 8 patients have survival follow-up ongoing.
“It’s very encouraging to see such outstanding survival from these patients extending beyond our 24-month trial protocol and without any subsequent treatment. OS surpassing two-years bodes well as we continue to monitor patients in our ongoing Phase 3 pivotal trial and in THIO-101 Part C,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “These results illuminate ateganosine’s valuable role in targeting telomeres to eliminate NSCLC tumor cells and support this treatment—ateganosine sequenced by a CPI—as a potential breakthrough therapeutic option for NSCLC.”
...
Read the full article here. -----
MAIA Recap - This NYSE American Breakout Idea Has 5 Explosive Potential Catalysts
#1. One Analyst's Target Suggests Over 1,000% Potential Upside From MAIA's Current Chart Levels.
#2. Another Analyst Target Suggests Over 700% Potential Upside From Tuesday's Close.
#3. A Phase 2 Expansion Trial Into The U.S. Signals A Key Company Milestone.
#4. A Recent $33Mn Capital Raise Aims To Completely Fund An Ongoing Pivotal Phase 3 Trial.
#5. The Company Reports Overall Survival Beyond 2 Years For 8 Patients In Ongoing Phase 2 Clinical Trial. -----
We're announcing coverage is officially underway on MAIA Biotechnology, Inc. (NYSE American: MAIA).
As soon as updates are available, we'll shoot them out to you quickly. Talk soon.
Sincerely, FierceAnalyst | Jaks Swift Editorial Writer
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
*FierceInvestor (FierceInvestor . com) is owned by SWN Media LLC, a limited liability company. Data is provided from third-party sources and FierceInvestor ("FI") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 04/29/2026 and ending on 04/29/2026 to publicly disseminate information about (MAIA:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC twenty thousand USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid two hundred eleven thousand two hundred fifty USD ("Funds"). These Funds were part of the ninety two thousand five hundred USD funds that TD Media LLC received from a third party named Sica Media LLC who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices.
Neither SWN Media LLC, TD Media LLC and their member own shares of (MAIA:US).
Please see important disclosure information here: https://fierceinvestor.com/disclosure/maia-obgqw/#details |
Tidak ada komentar:
Posting Komentar